A dedicated chemotherapy nurse is advocating for immediate action following her observations of a surge in breast cancer cases among individuals below 50 years old. Gemma, a 39-year-old NHS healthcare professional, is urging the UK to revise the mammogram screening age from 50 to 40 to address this concerning trend.
Expressing her concerns, Gemma Reeves, with nearly eight years of nursing experience, highlighted the shifting demographic of cancer patients post-Covid, emphasizing the increasing occurrence of breast cancer in younger women. She noted the challenges faced by these women, balancing cancer treatments while managing family and work responsibilities.
Currently, women in the UK are summoned for their initial NHS breast cancer screening between the ages of 50 and 53, with subsequent mammograms every three years until age 71. Despite the standard screening age, Gemma believes that the risk of breast cancer in younger women is escalating, a sentiment supported by official statistics.
According to data from Cancer Research UK, there has been a 14.4% rise in female breast cancer cases among 25 to 49-year-olds between 1993-1995 and 2018-2019 to 2021. Out of approximately 57,900 cases, around 9,700 occurred in this age group. While the increase aligns with trends in other age brackets, prominent US health organizations advocate for annual mammograms starting at age 40, a stance Gemma endorses for the UK.
In response to her concerns, Gemma initiated an online petition that has garnered over 30,000 signatures, aiming for parliamentary debate at 100,000 signatures. She stressed the urgency of adapting screening protocols to evolving risks and patient profiles, citing the growing number of younger patients diagnosed with advanced-stage cancer.
Despite differing opinions, with some experts cautioning against routine screening for breast cancer in younger individuals due to potential drawbacks like false positives, Gemma remains steadfast in her call for action. She emphasized the responsibility of screening teams to refer patients for further assessments when necessary, prioritizing early detection and treatment over procedural challenges.
While the Department of Health currently resists lowering the screening age or increasing frequency, citing UK NSC guidance, ongoing trials like AgeX with the NHS and Oxford University may influence future screening policies for women aged 47 to 49 and 71 to 73. The UK NSC is also examining additional breast screening for those with dense breast tissue, seeking input from stakeholders.
In conclusion, the debate around breast cancer screening for younger women continues, balancing the benefits of early detection against potential drawbacks. Gemma’s advocacy underscores the importance of adapting healthcare strategies to address evolving health trends and patient needs, sparking discussions on optimizing breast cancer screening protocols in the UK.